恩扎卢胺与阿比特龙治疗前列腺癌的主要不良心血管事件:一项回顾性队列研究
该回顾性队列研究纳入1999年12月1日至2021年3月31日期间在香港接受恩扎卢胺或阿比特龙联合雄激素剥夺治疗的成人前列腺癌患者,排除药物互换、未用激素起始阿比特龙及既往心脏事件者,随访至2021年9月30日。共分析1015例(恩扎卢胺456例,阿比特龙559例),中位随访11.3个月。恩扎卢胺组4P-MACE和CACE风险显著低于阿比特龙组。
要点
- 恩扎卢胺组4P-MACE风险显著低于阿比特龙组(wHR 0.71,95%CI 0.59-0.86,p<0.001)。
- 恩扎卢胺组CACE风险显著低于阿比特龙组(wHR 0.63,95%CI 0.42-0.96,p=0.031)。
- 恩扎卢胺组心肌梗死和全因死亡风险均显著低于阿比特龙组。
核心结论
- 在前列腺癌患者中,恩扎卢胺与比阿比特龙更低的心血管风险相关。
研究设计与样本
- 回顾性队列研究,纳入1999年12月1日至2021年3月31日期间在香港接受恩扎卢胺或阿比特龙联合雄激素剥夺治疗的成人前列腺癌患者,共分析1015例(恩扎卢胺456例,阿比特龙559例,平均年龄70.6±8.8岁),中位随访11.3个月(IQR 5.3-21.3),采用逆概率治疗加权平衡协变量。
主要发现
- 恩扎卢胺组4P-MACE风险显著低于阿比特龙组(wHR 0.71,95%CI 0.59-0.86,p<0.001),多变量分析结果一致。
- 恩扎卢胺组CACE风险显著低于阿比特龙组(wHR 0.63,95%CI 0.42-0.96,p=0.031)。
- 恩扎卢胺组心肌梗死风险显著低于阿比特龙组(wHR 0.57,95%CI 0.33-0.97,p=0.040)。
- 恩扎卢胺组全因死亡风险显著低于阿比特龙组(wHR 0.71,95%CI 0.59-0.85,p<0.001)。
- 该关联在年龄≥65岁或无糖尿病的患者中可能更强,且独立于双侧睾丸切除术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While the cardiovascular risks of androgen receptor pathway inhibitors have been studied, they were seldom compared directly. This study compares the risks of major adverse cardiovascular events (MACE) between enzalutamide and abiraterone among prostate cancer (PCa) patients. METHODS: Adult PCa patients receiving either enzalutamide or abiraterone in addition to androgen deprivation therapy in Hong Kong between 1 December 1999 and 31 March 2021 were identified in this retrospective cohort study. Patients who switched between enzalutamide and abiraterone, initiated abiraterone used without steroids, or experienced prior cardiac events were excluded. Patients were followed-up until 30 September 2021. The primary outcomes were MACE, a composite of stroke, myocardial infarction (MI), Heart failure (HF), or all-cause mortality and a composite of adverse cardiovascular events (CACE) not including all-cause mortality. The secondary outcomes were individual components of MACE. Inverse probability treatment weighting was used to balance covariates between treatment groups. RESULTS: In total, 1015 patients were analyzed (456 enzalutamide users and 559 abiraterone users; mean age 70.6 ± 8.8 years old) over a median follow-up duration of 11.3 (IQR: 5.3-21.3) months. Enzalutamide users had significantly lower risks of 4P-MACE (weighted hazard ratio (wHR) 0.71 [95% confidence interval (CI) 0.59-0.86], p < 0.001) and CACE (wHR 0.63 [95% CI: 0.42-0.96], p = 0.031), which remained consistent in multivariable analysis. Such an association may be stronger in patients aged ≥65 years or without diabetes mellitus and was independent of bilateral orchidectomy. Enzalutamide users also had significantly lower risks of MI (wHR 0.57 [95% CI: 0.33-0.97], p = 0.040) and all-cause mortality (wHR 0.71 [95% CI: 0.59-0.85], p < 0.001). CONCLUSION: Enzalutamide was associated with lower cardiovascular risks than abiraterone in PCa patients.
引用
- Lee YHA, Hui JMH, Leung CH, et al. Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostatic Dis. 2023. PMID: 38049634. doi:10.1038/s41391-023-00757-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。